Table 2.
Numbers of AEs and patients with AEs
| Article | Numbers of patients with AEs, n(%), Experimental; Ctrl | Numbers of AEs, n, experimental; Ctrl | Numbers of patients with SAEs, n(%), experimental; Ctrl | Numbers of SAEs, n, experimental; Ctrl | Number of AEs related to teatment, n |
|---|---|---|---|---|---|
| Lanzoni et al. [15] | 8(66.7) ; 11(91.67) | 46 ; 53 | 2(16.7) ; 8(66.7) | 6 ; 16 | 1* |
| Ventura-Carmenate et al. [16]** | 50(72.5) ; 51(72.9) | 107 ; 133 | NR ; NR | NR ; NR | 0 |
| Torres Zambrano et al. [17]** | NR ; NR | NR ; NR | NR ; NR | NR ; NR | NR |
| Shi et al. [18]*** | 37(56.9) ; 21(60) | 72 ; 36 | 1(1.5) ; 0 | 1 ; NR | 0 |
| Shi et al. [19]*** | 54(83.1) ; 26(74.3) | 106 ; 54 | 1(1.5) ; 0 | 1 ; NR | 0 |
| Zhu et al. [20] | 3(10.3) ; 13(44.8) | 20 ; 34 | 0 ; 0 | 0 ; 0 | 0 |
| Adas et al. [21] | NR ; NR | NR ; NR | NR ; NR | NR ; NR | NR |
| Dilogo et al. [22] | 0 ; NR | 0 ; NR | 0 ; NR | 0 ; NR | 0 |
| Torres Zambrano et al. [23]** | NR ; NR | NR ; NR | NR ; NR | NR ; NR | NR |
| Torres Zambrano et al. [24]** | NR ; NR | NR ; NR | NR ; NR | NR ; NR | NR |
| Wei et al. [25] | 1(8.3) ; NR | 3 ; NR | 1(8.3) ; NR | 3 ; NR | 0 |
| Xu et al. [26] | 20(76.9) ; 18(100) | 56 ; 59 | NR ; NR | 10 ; 15 | 0 |
| Meng et al. [27] | 3(33.3) ; NR | 4 ; NR | 0 ; NR | 0 ; NR | 3* |
| Häberle et al. [28] | NR ; NR | NR ; NR | NR ; NR | NR ; NR | NR |
| O.Ercelen et al. [29] | NR ; NR | NR; NR | 0 ; NR | 0 ; NR | 0 |
| Leng et al. [30] | NR ; NR | NR ; NR | 0 ; NR | 0 : NR | 0 |
| Shu et al. [31] | NR ; NR | NR ; NR | NR ; NR | NR ; NR | 0 |
AEs adverse events, SAEs serious adverse events
*The former study [15] mentioned three “infusion associated events” during the first round of infusion. The latter study [27] reported number of AEs in relationship to treatment and only one AE was considered “Probable”, which is the highest degree in reported relationship.
**These four studies are based on one clinical trial. The first study [16] focused on the safety and efficacy of stem cell therapy. The second study emphasized the radiographic outcome [17]. The third study [23] focused only on the renal involvement of the critically ill patients in the trial, and the last study [24] explored secondary sepsis and urinary tract infections in patients.
***These two studies are based on the same patients. The latter [19] is a one-year follow-up of the former and contains all AEs of the former [18].